Workflow
Cardiovascular Biopharmaceuticals
icon
Search documents
Cytokinetics to Present at the Stifel 2025 Virtual Cardiometabolic Forum
Globenewswireยท 2025-09-23 20:00
Core Insights - Cytokinetics is scheduled to present a corporate update at the Stifel 2025 Virtual Cardiometabolic Forum on September 30, 2025 [1] - The company is advancing a pipeline of potential new medicines for cardiac muscle dysfunction, including aficamten, a cardiac myosin inhibitor, which is nearing regulatory approvals following positive Phase 3 trial results [3] - Cytokinetics is also developing other treatments such as omecamtiv mecarbil for heart failure with reduced ejection fraction, ulacamten for heart failure with preserved ejection fraction, and CK-089 for muscular dystrophy [3] Company Overview - Cytokinetics is a specialty cardiovascular biopharmaceutical company with over 25 years of experience in muscle biology [3] - The company focuses on innovative treatments for patients suffering from diseases related to cardiac muscle dysfunction [3] - Aficamten is currently being evaluated in additional clinical trials for both obstructive and non-obstructive hypertrophic cardiomyopathy [3]
Cytokinetics Announces Three Upcoming Presentations at the HFSA Annual Scientific Meeting 2025
Globenewswireยท 2025-09-18 11:30
Core Insights - Cytokinetics is set to present significant findings related to Aficamten at the Heart Failure Society of America Annual Scientific Meeting 2025, including two Late Breaking Clinical Research presentations and one poster presentation [1][2]. Group 1: Presentations Overview - The first Late Breaking Clinical Research presentation will focus on the safety and efficacy of Aficamten in patients with nonobstructive hypertrophic cardiomyopathy, featuring a 96-week analysis from the FOREST-HCM study [2]. - The second Late Breaking Clinical Research presentation will analyze the divergent effects of Aficamten versus Metoprolol on exercise performance in obstructive hypertrophic cardiomyopathy, based on a prespecified analysis of the MAPLE-HCM study [2]. - A poster presentation will discuss the association of sociodemographic characteristics and healthcare costs in patients with non-obstructive hypertrophic cardiomyopathy [3]. Group 2: Aficamten Development - Aficamten is an investigational selective cardiac myosin inhibitor designed to reduce myocardial hypercontractility associated with hypertrophic cardiomyopathy (HCM) by binding to cardiac myosin [3][4]. - The drug is currently being evaluated in multiple clinical trials, including SEQUOIA-HCM for symptomatic obstructive HCM, ACACIA-HCM for non-obstructive HCM, and CEDAR-HCM for pediatric patients with obstructive HCM [5][6]. - Aficamten has received Breakthrough Therapy Designation from the FDA for symptomatic HCM and is under regulatory review in the U.S. and Europe, with a target action date of December 26, 2025, for the New Drug Application [4][6]. Group 3: Company Background - Cytokinetics is a biopharmaceutical company specializing in cardiovascular diseases, with over 25 years of experience in muscle biology and a focus on developing new medicines for cardiac muscle dysfunction [7]. - The company is preparing for potential regulatory approvals and commercialization of Aficamten following positive results from pivotal clinical trials [7].
Cytokinetics Announces Proposed Private Placement of $550.0 Million of Convertible Senior Notes
Globenewswireยท 2025-09-16 20:02
Core Viewpoint - Cytokinetics plans to offer $550 million in convertible senior notes due 2031, with an option for an additional $82.5 million, to support its business initiatives and potential commercial launch of aficamten [1][3]. Group 1: Offering Details - The offering consists of $550 million aggregate principal amount of convertible senior notes due 2031, intended for qualified institutional buyers [1]. - The notes will be senior, unsecured obligations, maturing on October 1, 2031, and will accrue interest payable semi-annually [2]. - Noteholders can convert their notes under certain conditions, with settlement options including cash, shares of common stock, or a combination [2]. Group 2: Use of Proceeds - A portion of the net proceeds will be used to pay cash consideration in note exchange transactions [3]. - Remaining proceeds will support the commercial launch of aficamten, expand its development program, advance its research pipeline, and cover general corporate purposes [3]. Group 3: Note Exchange Transactions - Cytokinetics plans to issue shares of common stock in exchange for a portion of its outstanding 3.50% convertible senior notes due 2027 in privately negotiated transactions [4]. - The terms of these note exchange transactions will depend on various factors, including market prices [4]. - There is no assurance on the amount or terms of the 2027 notes that will be exchanged [4]. Group 4: Market Activity Impact - Holders of the 2027 notes who hedge their equity price risk may unwind their positions by purchasing Cytokinetics' common stock, potentially affecting the market price [5]. - This activity could lead to a higher effective conversion price for the notes, although the magnitude of such market activity is unpredictable [5]. Group 5: Company Overview - Cytokinetics is a specialty cardiovascular biopharmaceutical company focused on developing new medicines for cardiac muscle dysfunction [8]. - The company is preparing for potential regulatory approvals and commercialization of aficamten, following positive Phase 3 trial results [9]. - Other developments include omecamtiv mecarbil for heart failure and ulacamten for heart failure with preserved ejection fraction [9].
Cytokinetics Announces Primary Results from MAPLE-HCM Presented at the European Society of Cardiology Congress 2025 and Published in The New England Journal Of Medicine
Globenewswireยท 2025-08-30 07:18
Core Insights - The primary results from the MAPLE-HCM trial indicate that aficamten demonstrates superiority over the standard-of-care beta-blocker metoprolol in improving exercise capacity in patients with obstructive hypertrophic cardiomyopathy (oHCM) [1][2][3] Company Overview - Cytokinetics is a biopharmaceutical company focused on developing treatments for cardiac muscle dysfunction, with aficamten being a key investigational drug currently under regulatory review in the U.S. and Europe [17][14] - Aficamten is a selective cardiac myosin inhibitor designed to reduce myocardial hypercontractility associated with hypertrophic cardiomyopathy (HCM) [11][12] Clinical Trial Details - The MAPLE-HCM trial is a Phase 3 randomized, double-blind study that enrolled 175 patients, comparing aficamten to metoprolol [2][4] - The primary endpoint was the mean change in peak oxygen uptake (pVO2) after 24 weeks, showing a significant improvement with aficamten (+1.1 mL/kg/min) compared to a decline with metoprolol (-1.2 mL/kg/min) [4][6] Efficacy Results - Aficamten showed a statistically significant least-squares mean difference of 2.3 mL/kg/min in pVO2 compared to metoprolol (p<0.0001) [4][6] - Aficamten also outperformed metoprolol in five of six secondary endpoints, including improvements in functional class and symptom burden [7][8] Safety Profile - The rate of adverse events was similar between aficamten and metoprolol, with aficamten showing a lower rate of treatment discontinuation due to adverse events [9] - Notably, hypertension was more common in the aficamten group, while dizziness was more prevalent in the metoprolol group [9] Regulatory Status - Aficamten is currently under review by the FDA with a target action date of December 26, 2025, and is also being evaluated by the European Medicines Agency [14][12]
Cytokinetics to Announce Second Quarter Results On August 7, 2025
Globenewswireยท 2025-07-24 20:00
Company Overview - Cytokinetics is a specialty cardiovascular biopharmaceutical company with over 25 years of experience in muscle biology and is focused on developing new medicines for cardiac muscle dysfunction [3] - The company is preparing for potential regulatory approvals and commercialization of aficamten, a cardiac myosin inhibitor, following positive results from the SEQUOIA-HCM Phase 3 clinical trial [3] - Cytokinetics is also developing omecamtiv mecarbil for heart failure with severely reduced ejection fraction (HFrEF), CK-586 for heart failure with preserved ejection fraction (HFpEF), and CK-089 for specific muscular dystrophies and impaired skeletal muscle function [3] Upcoming Events - Cytokinetics is scheduled to report its second quarter results on August 7, 2025, at 4:00 PM Eastern Time [1] - Following the results announcement, a conference call will be held at 4:30 PM Eastern Time to discuss financial results and provide business updates [1][2] - The conference call will be available via webcast and an archived replay will be accessible for six months [2]
Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2025
Globenewswireยท 2025-07-10 11:30
Core Insights - Cytokinetics is set to present five key studies related to aficamten at the European Society of Cardiology Congress 2025, highlighting its potential in treating obstructive hypertrophic cardiomyopathy (HCM) [1][4] - The MAPLE-HCM trial compares aficamten with metoprolol, focusing on exercise capacity in patients with left ventricular outflow tract (LVOT) obstruction [2][4] - A late-breaking presentation will address the incidence and impact of atrial fibrillation across three clinical trials involving aficamten [1][2] Presentation Details - The MAPLE-HCM presentation will be led by Dr. Pablo Garcia-Pavia on August 30, 2025, at 9:18 AM CEST in Madrid [2] - The late-breaking clinical science presentation on atrial fibrillation will be conducted by Dr. Ahmad Masri on August 31, 2025, at 4:45 PM CEST in Budapest [2] - Another presentation on the long-term efficacy and safety of aficamten will be given by Dr. Sara Saberi on August 31, 2025, at 5:40 PM CEST [2] Additional Research - A poster presentation will analyze the effect of aficamten compared to metoprolol on cardiac structure and function in symptomatic obstructive HCM [3] - An integrated safety analysis of aficamten in patients with obstructive HCM will also be presented [3] Company Overview - Cytokinetics is a biopharmaceutical company specializing in cardiovascular diseases, with over 25 years of experience in muscle biology [4] - The company is preparing for potential regulatory approvals and commercialization of aficamten following positive results from the SEQUOIA-HCM trial [4] - Cytokinetics is also developing other drug candidates targeting heart failure and muscular dystrophy [4]
Cytokinetics Announces Call For Proposals For Annual Corporate Giving Program
Globenewswireยท 2025-06-10 11:30
Group 1: Corporate Giving Program - Cytokinetics has announced its annual Corporate Giving Program, which aims to provide charitable donations to eligible non-profit organizations in the U.S. to support equitable healthcare initiatives, diversity in science education, and essential services for local and at-risk communities [2][3] - The program offers individual charitable donations of up to $20,000 for qualified 501(c)(3) organizations that are not directly involved in healthcare practices [3] - Applications for the program can be submitted online, with a deadline set for August 4, 2025 [3] Group 2: Corporate Values and Impact - The Corporate Giving Program is designed to partner with non-profit organizations to advance shared missions, particularly focusing on health equity in cardiovascular disease [3] - Cytokinetics aims to expand its impact in its second year of formalized corporate giving, building on the foundation established in 2024 [3] Group 3: Company Overview - Cytokinetics is a specialty cardiovascular biopharmaceutical company with over 25 years of experience in muscle biology, focusing on developing new medicines for cardiac muscle dysfunction [4] - The company is preparing for potential regulatory approvals and commercialization of aficamten, a cardiac myosin inhibitor, following positive results from the SEQUOIA-HCM Phase 3 clinical trial [4] - Cytokinetics is also developing other product candidates, including omecamtiv mecarbil for heart failure, CK-586 for heart failure with preserved ejection fraction, and CK-089 for muscular dystrophy [4]
Cytokinetics to Host Symposium on Contemporary Landscapes in Muscle Biology
Globenewswireยท 2025-05-15 11:30
Core Insights - Cytokinetics is hosting the second annual Contemporary Landscapes in Muscle Biology Research Symposium (CLIMB) on May 30, 2025, in San Francisco, CA, aimed at fostering scientific exchange in muscle biology [2][3] - The symposium will feature expert speakers and poster presentations focusing on innovations in cardiac and skeletal muscle biology, as well as emerging treatment modalities [3][6] - Cytokinetics is advancing a pipeline of potential new medicines for cardiac muscle dysfunction, including aficamten, which is undergoing regulatory approval following positive Phase 3 trial results [5] Company Overview - Cytokinetics is a specialty cardiovascular biopharmaceutical company with over 25 years of experience in muscle biology [5] - The company is developing several drug candidates, including aficamten for obstructive hypertrophic cardiomyopathy (HCM) and omecamtiv mecarbil for heart failure with severely reduced ejection fraction (HFrEF) [5] - Other candidates in development include CK-586 for heart failure with preserved ejection fraction (HFpEF) and CK-089 for specific types of muscular dystrophy [5] Event Details - The CLIMB symposium aims to promote collaboration and networking among scientists and researchers in the field of muscle biology [3] - Registration for the event is open until May 23, 2025 [4] - Keynote speakers include prominent figures from various institutions, highlighting the interdisciplinary nature of the symposium [6]
Cytokinetics Announces Four Upcoming Presentations at the European Society Of Cardiology Heart Failure 2025 Congress
GlobeNewswire News Roomยท 2025-05-08 20:00
Core Insights - Cytokinetics is set to present three Late Breaking Science presentations and one ePoster at the Heart Failure 2025 congress in Belgrade, Serbia from May 17 to May 20, 2025 [1] Group 1: Late Breaking Science Presentations - The first presentation will focus on the efficacy and safety of Aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms, presented by Dr. Iacopo Olivotto on May 17, 2025 [2] - The second presentation will discuss the effect of Aficamten treatment on patients with hypertrophic obstructive cardiomyopathy by geographical region, presented by Dr. Caroline Coats on May 18, 2025 [2] - The third presentation will analyze the effect of Omecamtiv Mecarbil on outcomes using the Win Ratio, as part of an exploratory analysis of the GALACTIC-HF trial, presented by Dr. Kieran F. Docherty on May 19, 2025 [2] Group 2: ePoster Presentation - An ePoster will be presented by Dr. Paulos Gebrehiwet on May 17, 2025, discussing the associations between age and sex and cardiovascular outcomes in patients with non-obstructive hypertrophic cardiomyopathy [3] Group 3: Company Overview - Cytokinetics is a specialty cardiovascular biopharmaceutical company with over 25 years of experience in muscle biology, focusing on developing new medicines for cardiac muscle dysfunction [4] - The company is preparing for potential regulatory approvals and commercialization of Aficamten, following positive results from the SEQUOIA-HCM Phase 3 clinical trial [4] - Cytokinetics is also developing Omecamtiv Mecarbil for heart failure with severely reduced ejection fraction, CK-586 for heart failure with preserved ejection fraction, and CK-089 for specific muscular dystrophies and other conditions [4]
Cytokinetics to Hold Annual Meeting of Stockholders
Globenewswireยท 2025-05-07 20:00
Company Overview - Cytokinetics is a specialty cardiovascular biopharmaceutical company with over 25 years of experience in muscle biology, focusing on developing new medicines for cardiac muscle dysfunction [4] - The company is preparing for potential regulatory approvals and commercialization of aficamten, a cardiac myosin inhibitor, following positive results from the SEQUOIA-HCM Phase 3 clinical trial [4] - Other products in development include omecamtiv mecarbil for heart failure with severely reduced ejection fraction (HFrEF), CK-586 for heart failure with preserved ejection fraction (HFpEF), and CK-089 for specific muscular dystrophies [4] Annual Meeting Details - Cytokinetics will hold its Annual Meeting of Stockholders on May 14, 2025, at 10:00 AM Pacific Time at its headquarters in South San Francisco [1] - Stockholders of record as of March 24, 2025, are entitled to vote or attend the meeting in person [2] - A live webcast of the meeting and subsequent company update presentation will be available, with an archived replay accessible for twelve months [3]